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Tacalcitol
A Viewpoint b y  P.C.M. van de Kerkhof
Department of Dermatology/
University Hospital Nijmegen,
Nijmegen, The Netherlands
Topical vitamin D3 analogues have revolutionised 
the management of psoriasis. The first analogues 
which were introduced for the management of pso­
riasis were calcipotriol and tacalcitol. The intro­
duction of calcipotriol was worldwide, whereas the 
introduction of tacalcitol was restricted to Japan.
The usefulness of calcipotriol as monotherapy 
and combination therapy has been demonstrated 
clearly in many large controlled studies.
Recently, tacalcitol has been introduced in some 
European countries as a 4 |ag/g preparation, in­
tended for once-daily treatment. Tacalcitol is more 
effective than placebo, with efficacy approaching 
that of medium potency corticosteroids.
Comparative studies between vitamin D3 ana­
logues are required to determine their usefulness, 
specific indications and limitations.
Tacalcitol
A Viewpoint b y  J. Baral and M. Lebwohl
Mount Sinai School of Medicine, New York,
New York, USA
Over the past decade vitamin D3 analogues have 
been introduced for the management of psoriasis. 
Of the vitamin D3 analogues currently available, 
calcipotriol (calcipotriene) is one of the most 
widely prescribed and was the only one approved 
for psoriasis in the United States prior to 1997. In 
terms of effectiveness alone, this class of agents
does not constitute a major breakthrough in the 
treatment of the disease. They are not as effective 
as PUVA, methotrexate or cyclosporin, or as effec­
tive for short term therapy as high-potency topical 
steroids.
In terms of tolerabiiity, however, vitamin D3 an­
alogues offer major advantages over other treat­
ments. The cutaneous carcinogenicity of PUVA, 
hepatotoxicity of methotrexate and nephrotoxicity 
of cyclosporin are not seen with this class of agents. 
Unlike topical steroids, vitamin D3 analogues do 
not cause cutaneous atrophy, telangiectasia or 
striae and there is some evidence that they may 
thicken the skin; moreover, they do not appear to 
be associated with tachyphylaxis during regular 
use. The only common adverse effect of tacalcitol 
is local cutaneous irritation, which can affect up to 
20% of patients. Hypercalcaemia and hypercalci- 
uria have been reported with overuse of calcipo­
triol and mild hypercalcaemia has occurred occa­
sionally, even with doses in the therapeutic range. 
In contrast, tacalcitol has not been shown to raise 
serum calcium levels.
Published data suggest that tacalcitol is compa­
rable to betamethasone valerate, while at least one 
study shows calcipotriol to be superior to the potent 
topical steroid fluocinonide. Direct comparisons 
between tacalcitol and calcipotriol will be neces­
sary, but the introduction of vitamin D3 analogues 
for the treatment of psoriasis has had a significant 
impact on our ability to treat psoriasis patients top­
ically. These are the first of what is hoped will be 
an entirely new class of agents for treating disor­
ders of keratinisation.
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